Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking strategy to diabetes management. These innovative drugs operate by mimicking the natural actions of GLP-1, a hormone produced by the gut in response to meals. By stimulating GLP-1 receptors in the pancreas, these agents boost insulin release and inhibit glucagon release

The burgeoning landscape of innovative treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight loss – they exhibit intriguing contrasts in their